Association between HSP90 and Her2 in Gastric and Gastroesophageal Carcinomas

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Berezowska, Sabina ^a   Novotny, Alexander ^b   Bauer, Karina ^c   Feuchtinger, Annette ^d   Slotta Huspenina, Julia ^c   Becker, Karen ^c   Langer, Rupert ^a   Walch, Axel ^d  

^a UNIVERSITY OF BERN   (Switzerland)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOMA; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROESOPHAGEAL CARCINOMA; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; ESOPHAGOGASTRIC JUNCTION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84880081657     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069098     Document Type: Article

References (66)

1. Hechtman JF, Polydorides AD, (2012) HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med 136: 691-697. doi:10.5858/arpa.2011-0168-RS. PubMed: 22646280.
2. Jørgensen JT, Hersom M, (2012) HER2 as a Prognostic Marker in Gastric Cancer- A Systematic Analysis of Data from the Literature. J Cancer 3: 137-144. doi:10.7150/jca.4090. PubMed: 22481979.
3. Chua TC, Merrett ND, (2012) Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review. Int J Cancer 130: 2845-2856. doi:10.1002/ijc.26292. PubMed: 21780108.
4. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697. doi:10.1016/S0140-6736(10)61121-X. PubMed: 20728210.
5. Shitara K, Yatabe Y, Matsuo K, Sugano M, Kondo C, et al. (2013) Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. Gastric Cancer 16: 261-267. doi:10.1007/s10120-012-0179-9. PubMed: 22797858.
6. Grávalos C, Gómez-Martín C, Rivera F, Alés I, Queralt B, et al. (2011) Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol 13: 179-184. doi:10.1007/s12094-011-0637-6. PubMed: 21421462.
7. Maresch J, Schoppmann SF, Thallinger CM, Zielinski CC, Hejna M, (2012) Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment. Crit Rev Oncol/Hematol 82: 310-322. doi:10.1016/j.critrevonc.2011.06.003. PubMed: 21783379.
8. Sidera K, Gaitanou M, Stellas D, Matsas R, Patsavoudi E, (2008) A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J Biol Chem 283: 2031-2041. PubMed: 18056992.
9. Citri A, Harari D, Shohat G, Ramakrishnan P, Gan J, et al. (2006) Hsp90 recognizes a common surface on client kinases. J Biol Chem 281: 14361-14369. doi:10.1074/jbc.M512613200. PubMed: 16551624.
10. Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, et al. (2007) Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther 6: 1123-1132. doi:10.1158/1535-7163.MCT-06-0628. PubMed: 17363505.
11. Neckers L, Workman P, (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18: 64-76. doi:10.1158/1078-0432.MECHRES-B64. PubMed: 22215907.
12. Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, et al. (2011) HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 17: 5132-5139. doi:10.1158/1078-0432.CCR-11-0072. PubMed: 21558407.
13. Scaltriti M, Serra V, Normant E, Guzman M, Rodriguez O, et al. (2011) Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer. Mol Cancer Ther 10: 817-824. doi:10.1158/1535-7163.MCT-10-0966. PubMed: 21383049.
14. Lu C, Liu D, Jin J, Deokar H, Zhang Y, et al. (2013) Inhibition of gastric tumor growth by a novel Hsp90 inhibitor. Biochem Pharmacol 85: 1246-1256. doi:10.1016/j.bcp.2013.02.003. PubMed: 23415900.
15. Giaginis C, Daskalopoulou SS, Vgenopoulou S, Sfiniadakis I, Kouraklis G, et al. (2009) Heat Shock Protein-27,-60 and-90 expression in gastric cancer: association with clinicopathological variables and patient survival. BMC Gastroenterol 9: 14. doi:10.1186/1471-230X-9-14. PubMed: 19203381.
16. Buffart TE, Carvalho B, van Grieken NC, van Wieringen WN, Tijssen M, et al. (2012) Losses of chromosome 5q and 14q are associated with favorable clinical outcome of patients with gastric cancer. Oncologist 17: 653-662. doi:10.1634/theoncologist.2010-0379. PubMed: 22531355.
17. Wang J, Cui S, Zhang X, Wu Y, Tang H, (2013) High expression of heat shock protein 90 is associated with tumor aggressiveness and poor prognosis in patients with advanced gastric cancer. PLOS ONE 8: e62876. doi:10.1371/journal.pone.0062876. PubMed: 23638161.
18. Sobin L, Gospodarowicz ML, Wittekind C, (2010) TNM classification of malignant tumors; New York: John Wiley & Sons.
19. Balluff B, Elsner M, Kowarsch A, Rauser S, Meding S, et al. (2010) Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier. J Proteome Res 9: 6317-6322. doi:10.1021/pr100573s. PubMed: 21058730.
20. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, et al. (2012) HER2 testing in gastric cancer: a practical approach. Mod Pathol 25: 637-650. doi:10.1038/modpathol.2011.198. PubMed: 22222640.
21. Rauser S, Weis R, Braselmann H, Feith M, Stein HJ, et al. (2007) Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues. Clin Cancer Res 13: 5115-5123. doi:10.1158/1078-0432.CCR-07-0465. PubMed: 17785566.
22. Walch A, Specht K, Braselmann H, Stein H, Siewert JR, et al. (2004) Coamplification and coexpression of GRB7 and ERBB2 is found in high grade intraepithelial neoplasia and in invasive Barrett's carcinoma. Int J Cancer 112: 747-753. doi:10.1002/ijc.20411. PubMed: 15386389.
23. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, et al. (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52: 797-805. doi:10.1111/j.1365-2559.2008.03028.x. PubMed: 18422971.
24. EMEA (2009) Committee for medicinal products for human use post-authorisation summary of positive opinion for herceptin. Available: www.emea.europa.eu/pdfs/human/opinion/Herceptin_82246709en.pdf. Accessed 2013 March 1.
25. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, et al. (2005) Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-278. doi:10.1093/annonc/mdi064. PubMed: 15668283.
26. Grillo F, Fassan M, Ceccaroli C, Giacometti C, Curto M, et al. (2013) The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples. Transl Oncol 6: 10-16. PubMed: 23418612.
27. Lee HE, Park KU, Yoo SB, Nam SK, Park do J, et al. (2013) Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer 49: 1448-1457. doi:10.1016/j.ejca.2012.10.018. PubMed: 23146959.
28. Warneke VS, Behrens HM, Böger C, Becker T, Lordick F, et al. (2013) Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol 24: 725-733. doi:10.1093/annonc/mds528. PubMed: 23139264.
29. Ilyas M, Grabsch H, Ellis IO, Womack C, Brown R, et al. (2013) Guidelines and considerations for conducting experiments using tissue microarrays. Histopathology 62: 827-839. doi:10.1111/his.12118. PubMed: 23672312.
30. Thomson TA, Zhou C, Chu C, Knight B, (2009) Tissue microarray for routine analysis of breast biomarkers in the clinical laboratory. Am J Clin Pathol 132: 899-905. doi:10.1309/AJCPW37QGECDYCDO. PubMed: 19926582.
31. Zhang D, Salto-Tellez M, Do E, Putti TC, Koay ES, (2003) Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol 34: 362-368. doi:10.1053/hupa.2003.60. PubMed: 12733117.
32. Pirrelli M, Caruso ML, Di Maggio M, Armentano R, Valentini AM, (2013) Are biopsy specimens predictive of HER2 status in gastric cancer patients? Dig Dis Sci 58: 397-404. PubMed: 22918687.
33. Yang J, Luo H, Li Y, Li J, Cai Z, et al. (2012) Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys 62: 221-228. doi:10.1007/s12013-011-9286-1. PubMed: 21927816.
34. Yoon Cho E, Park K, Do I, Cho J, Kim J, et al. (2013) Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas. Mod Pathol 26: 677-684. doi:10.1038/modpathol.2012.205. PubMed: 23238628.
35. Walch A, Specht K, Bink K, Zitzelsberger H, Braselmann H, et al. (2001) Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. Lab Invest 81: 791-801. doi:10.1038/labinvest.3780289. PubMed: 11406641.
36. Langer R, Rauser S, Feith M, Nährig JM, Feuchtinger A, et al. (2011) Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. Mod Pathol 24: 908-916. doi:10.1038/modpathol.2011.52. PubMed: 21516080.
37. Tse CH, Hwang HC, Goldstein LC, Kandalaft PL, Wiley JC, et al. (2011) Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. J Clin Oncol 29: 4168-4174. doi:10.1200/JCO.2011.36.0107. PubMed: 21947821.
38. Vranic S, Teruya B, Repertinger S, Ulmer P, Hagenkord J, et al. (2011) Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer 117: 48-53. doi:10.1002/cncr.25580. PubMed: 20803611.
39. Marchiò C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C, et al. (2009) Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 219: 16-24. doi:10.1002/path.2574. PubMed: 19670217.
40. Vani K, Sompuram SR, Fitzgibbons P, Bogen SA, (2008) National HER2 proficiency test results using standardized quantitative controls: characterization of laboratory failures. Arch Pathol Lab Med 132: 211-216. PubMed: 18251579.
41. Hicks DG, Tubbs RR, (2005) Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol 36: 250-261. doi:10.1016/j.humpath.2004.11.010. PubMed: 15791569.
42. Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Rüschoff J, et al. (2007) Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod Pathol 20: 584-591. doi:10.1038/modpathol.3800774. PubMed: 17396141.
43. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145. PubMed: 17159189.
44. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF, (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27: 1323-1333. doi:10.1200/JCO.2007.14.8197. PubMed: 19204209.
45. Dekker TJ, Borg ST, Hooijer GK, Meijer SL, Wesseling J, et al. (2012) Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Res 14: R93. doi:10.1186/bcr3208. PubMed: 22694844.
46. Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, et al. (2012) Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 18: 5992-6000. doi:10.1158/1078-0432.CCR-12-1318. PubMed: 22977193.
47. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, et al. (2012) Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 23: 2656-2662. doi:10.1093/annonc/mds104. PubMed: 22689179.
48. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W, (2010) HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value- conclusions from 924 cases of two independent series. Cell Oncol 32: 57-65. PubMed: 20208134.
49. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, et al. (2012) Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 18: 546-554. doi:10.1158/1078-0432.CCR-11-2272. PubMed: 22252257.
50. Hicks DG, Kulkarni S, (2008) HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol 129: 263-273. doi:10.1309/99AE032R9FM8WND1. PubMed: 18208807.
51. Lindquist S, Craig EA, (1988) The heat-shock proteins. Annu Rev Genet 22: 631-677. doi:10.1146/annurev.ge.22.120188.003215. PubMed: 2853609.
52. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR, (2006) Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 31: 164-172. doi:10.1016/j.tibs.2006.01.006. PubMed: 16483782.
53. Ciocca DR, Calderwood SK, (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10: 86-103. doi:10.1379/CSC-99r.1. PubMed: 16038406.
54. Porter JR, Fritz CC, Depew KM, (2010) Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol 14: 412-420. doi:10.1016/j.cbpa.2010.03.019. PubMed: 20409745.
55. Hong DS, Banerji U, Tavana B, George GC, Aaron J, et al. (2013) Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev 39: 375-387. doi:10.1016/j.ctrv.2012.10.001. PubMed: 23199899.
56. Scaltriti M, Dawood S, Cortes J, (2012) Molecular pathways: targeting hsp90--who benefits and who does not. Clin Cancer Res 18: 4508-4513. doi:10.1158/1078-0432.CCR-11-2138. PubMed: 22718860.
57. Lu X, Xiao L, Wang L, Ruden DM, (2012) Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. Biochem Pharmacol 83: 995-1004. doi:10.1016/j.bcp.2011.11.011. PubMed: 22120678.
58. Patel HJ, Modi S, Chiosis G, Taldone T, (2011) Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expert Opin Drugs Discov 6: 559-587. doi:10.1517/17460441.2011.563296. PubMed: 22400044.
59. Jego G, Hazoumé A, Seigneuric R, Garrido C, (2013) Targeting heat shock proteins in cancer. Cancer Lett 332: 275-285. doi:10.1016/j.canlet.2010.10.014. PubMed: 21078542.
60. Lee KH, Lee JH, Han SW, Im SA, Kim TY, et al. (2011) Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. Cancer Sci 102: 1388-1395. doi:10.1111/j.1349-7006.2011.01944.x. PubMed: 21453385.
61. Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, et al. (2012) Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. Cancer Sci 103: 342-349. doi:10.1111/j.1349-7006.2011.02144.x. PubMed: 22050138.
62. Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, et al. (2010) Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 29: 325-334. doi:10.1038/onc.2009.337. PubMed: 19855434.
63. Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, et al. (2013) Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer. Mol Cancer Ther 12: 509-519. doi:10.1158/1535-7163.MCT-12-0507. PubMed: 23395886.
64. Chen CY, Chen CY, (2010) Insights into designing the dual-targeted HER2/HSP90 inhibitors. J Mol Graph Modell 29: 21-31. doi:10.1016/j.jmgm.2010.04.002. PubMed: 20471294.
65. Citri A, Kochupurakkal BS, Yarden Y, (2004) The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 3: 51-60. PubMed: 14657666.
66. Jhaveri K, Taldone T, Modi S, Chiosis G, (2012) Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 1823: 742-755. doi:10.1016/j.bbamcr.2011.10.008. PubMed: 22062686.